Newsfeeds - Spark Newswire

3 minute read

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet

Today, 12:44 PM

Investors are on the hunt for undervalued, underfollowed and emerging stocks when it comes to spotting opportunities. Retail traders have countless methods at their disposal to uncover new information.

AMD

6 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 12:44 PM

Tuesday's morning session saw 84 companies set new 52-week lows.

AAP

1 minute read

Credit Suisse Upgrades Esperion Therapeutics to Neutral, Raises Price Target to $7

By Benzinga Newsdesk

Today, 12:44 PM

Credit Suisse analyst Judah Frommer upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underperform to Neutral and raises the price target from $6.5 to $7.

ESPR

3 minute read

Nasdaq Rises 50 Points; Ciena Earnings Top Expectations

By Lisa Levin

Today, 12:44 PM

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P 500 also rose, gaining, 0.35% to 4,059.80.

ACRS

3 minute read

Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher

By Lisa Levin

Today, 12:44 PM

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500 also rose, gaining, 0.69% to 4,073.40.

ACRS

2 minute read

Esperion Therapeutics Stock Is Diving: What’s Going On?

By Adam Eckert

Today, 12:44 PM

Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at

ESPR

1 minute read

Needham Maintains Buy on Esperion Therapeutics, Raises Price Target to $16

By Benzinga Newsdesk

Today, 12:44 PM

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and raises the price target from $12 to $16.

ESPR

1 minute read

Esperion Long Term Data On Cholesterol Medication’s Ability To Cut Cardiovascular Risk Fails To Impress Investors

By Vandana Singh

Today, 12:44 PM

Esperion Therapeutics Inc (NASDAQ:ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with…

ESPR

1 minute read

Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, February 28, 2023: GME, WYNN, TWLO, CHPT, ESPR

By Benzinga Newsdesk

Today, 12:44 PM

GameStop (GME) - A potential peer play amid upcoming quarterly results from AMC Entertainment (AMC). AMC will report earnings after market close Tuesday. Wynn Resorts (WYNN)

CHPT

1 minute read

Needham Reiterates Buy on Esperion Therapeutics, Maintains $12 Price Target

By Benzinga Newsdesk

Today, 12:44 PM

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $12 price target.

ESPR